Stay updated on Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding status notice and Revision: v3.4.1; these are footer/system-level updates that do not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding lapse notice indicating the NIH Clinical Center is open and where to check status. Updated site version to v3.4.1 and removed v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary display; updated the QC-related label to 'Last Update Submitted that Met QC Criteria' and revised FEAR Act data and version text (Revision: v3.4.0), while removing the prior wording (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page no longer lists the condition Head and neck squamous cell carcinoma and removes related topics such as MedlinePlus Genetics.SummaryDifference0.1%

- Check57 days agoChange DetectedAdded related topic links: Head and neck squamous cell carcinoma and MedlinePlus Genetics; no changes to the study details or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations section added with a comprehensive list of sites (Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Louisiana, Maryland, Michigan, Minnesota, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia, Ontario). The update replaces the previous per-location headings and removes the HHS Vulnerability Disclosure link.SummaryDifference2%

Stay in the know with updates to Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.